By Colin Kellaher
Dermata Therapeutics shares jumped more than 50% in early trading Thursday after the biotechnology company said its Xyngari once-weekly, topical product candidate for the treatment of moderate-to-severe acne hit its goals in a late-stage study.
Shares of the San Diego company were recently changing hands at $2.05, up 52%.
Dermata said Xyngari met all three primary endpoints in the Phase 3 study by achieving a statistically significant difference when compared with placebo after 12 weeks.
Dermata said it plans to launch a second Phase 3 study in the second half of the year followed by an open-label extension study, adding that positive Phase 3 program will help support the filing of a new-drug application with the U.S. Food and Drug Administration.
The company said it also plans to hold talks with potential partners interested in securing future rights to Xyngari.
Dermata said it believes a once-weekly topical acne product like Xyngari could lead to improved patient compliance, as all current FDA-approved topical products need to be applied at least once or twice a day.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 27, 2025 09:57 ET (13:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。